• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Vertex Pharmaceuticals

Vertex Pharmaceuticals

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases

    Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases

  2. Five Consensus Views that Could Prove Wrong in 2015

    Options on this firm's blockbuster cost a little but pay off big.

  3. A Favorable Prognosis for This Pharma Stock

    Recent clinical success in cystic fibrosis positions Vertex as a dominant player in this attractive rare-disease market.

  4. Reinvent Your Practice: Alternatives to Traditional Succession Planning

    Following is a roundup of stocks that recently jumped to 5 stars in the last week. By way of background, we award a stock 5 stars when it trades at a suitably large discount--i.e., a margin of safety--to our fair value estimate. Thus, when a stock hits 5-star territory, we consider it an especially ...

  5. Gilead Sciences Carving Out a Wider Moat

    StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.

  6. How Did Facebook End Up in the S&P 500?

    We dive into the process for adding companies and booting them from the iconic index.

  7. Pharmaceutical Firms Get the Urge to Merge

    Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.

  8. Morningstar Indexes: Weekly Market Report

    Week ending Oct. 27: Stocks held in check by jump oil prices, weak housing market.

  9. Best Positioned for Health-Care Reform

    This screen finds companies ready to take advantage when major provisions of law take effect in 2014.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.